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Background
The capacity of immune complexes to augment antibody
(Ab) responses is well established. The enhancing effects
of immune complexes have been attributed mainly to Fc-
mediated adjuvant activity. On the other hand, antigenic
alterations of specific epitopes as a result of immune com-
plex formation have been less well studied.
Methods
We probed for alterations in the antigenicity of HIV
gp120/Ab complexes using ELISA with monoclonal Abs
specific for different gp120 regions. The immunogenicity
of the gp120/Ab complexes was evaluated in mice immu-
nized with the complexes.
Results
The data show that gp120/Ab complexes display higher
reactivity with mAbs to the neutralizing epitopes on the
V3 loop. Enhanced Ab responses to the V3 loop were
detected in mice immunized with thegp120/Ab com-
plexes. Importantly, potent neutralizing activity was
observed in the sera immunized with the complexes, but
not in the sera of mice immunized with uncomplexed
gp120. However, the neutralization was highly restricted
to the homologous HIV-1LAI strain. When the immune
complexes were prepared using gp120 from a more repre-
sentative subtype B HIV-1 strain (JRFL), high titers of Ab
responses with distinct fine specificity were induced in the
sera of immunized mice, but the breadth of serum neu-
tralizing activity was still limited.
Conclusion
The binding of Abs to gp120 alters the antigenicity and
immunogenicity of gp120, leading to enhanced potency
of Ab responses against the neutralizing V3 epitopes.
However, further studies are necessary to improve the
breadth of the neutralizing Ab responses.
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